There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on US Physical Therapy (USPH – Research Report) and Calliditas Therapeutics (CALT – Research Report) with bullish sentiments.
US Physical Therapy (USPH)
Barrington analyst Michael Petusky maintained a Buy rating on US Physical Therapy today and set a price target of $124.00. The company’s shares closed last Thursday at $95.44.
According to TipRanks.com, Petusky is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for US Physical Therapy with a $126.33 average price target, a 32.1% upside from current levels. In a report issued on September 19, CJS Securities also upgraded the stock to Buy.
See the top stocks recommended by analysts >>
Calliditas Therapeutics (CALT)
H.C. Wainwright analyst Arthur He CFA maintained a Buy rating on Calliditas Therapeutics today and set a price target of $50.00. The company’s shares closed last Thursday at $18.64.
According to TipRanks.com, CFA has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Calliditas Therapeutics with a $31.58 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on USPH:
- U.S. Physical Therapy upgraded to Outperform from Market Perform at CJS Securities
- U.S. Physical Therapy price target raised to $124 from $116 at Barrington
- U.S. Physical Therapy reports Q2 EPS 64c, consensus 75c
- U.S. Physical Therapy acquires 70% stake in five clinic practice for $2.1M
- USPH Earnings Report this Week: Is It a Buy, Ahead of Earnings?
